Rockwell Medical Inc (RMTI)

$2.13

+0.02

(+1.19%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Rockwell Medical Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 22.09M → 22.67M (in $), with an average increase of 2.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -1.51M → -1.73M (in $), with an average decrease of 14.5% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 53.5% return, outperforming this stock by 101.7%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 51.7% return, outperforming this stock by 127.8%

Performance

  • $2.08
    $2.28
    $2.13
    downward going graph

    2.32%

    Downside

    Day's Volatility :8.75%

    Upside

    6.58%

    downward going graph
  • $1.16
    $4.49
    $2.13
    downward going graph

    45.54%

    Downside

    52 Weeks Volatility :74.16%

    Upside

    52.56%

    downward going graph

Returns

PeriodRockwell Medical IncIndex (Russel 2000)
3 Months
39.67%
0.0%
6 Months
43.92%
0.0%
1 Year
-48.18%
0.0%
3 Years
-76.09%
-21.0%

Highlights

Market Capitalization
58.5M
Book Value
$0.7
Earnings Per Share (EPS)
-0.33
PEG Ratio
-0.79
Wall Street Target Price
7.0
Profit Margin
-9.72%
Operating Margin TTM
-5.84%
Return On Assets TTM
-9.0%
Return On Equity TTM
-50.75%
Revenue TTM
86.6M
Revenue Per Share TTM
2.93
Quarterly Revenue Growth YOY
15.299999999999999%
Gross Profit TTM
4.1M
EBITDA
-4.7M
Diluted Eps TTM
-0.33
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.13
EPS Estimate Next Year
0.02
EPS Estimate Current Quarter
-0.04
EPS Estimate Next Quarter
-0.03

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Rockwell Medical Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 228.64%

Current $2.13
Target $7.00

Company Financials

FY18Y/Y Change
Revenue
63.4M
↑ 10.63%
Net Income
-32.1M
↑ 23.94%
Net Profit Margin
-50.68%
↓ 5.44%
FY19Y/Y Change
Revenue
61.3M
↓ 3.29%
Net Income
-31.1M
↓ 3.26%
Net Profit Margin
-50.7%
↓ 0.02%
FY20Y/Y Change
Revenue
62.2M
↑ 1.46%
Net Income
-31.9M
↑ 2.75%
Net Profit Margin
-51.34%
↓ 0.64%
FY21Y/Y Change
Revenue
61.9M
↓ 0.43%
Net Income
-35.0M
↑ 9.71%
Net Profit Margin
-56.57%
↓ 5.23%
FY22Y/Y Change
Revenue
72.8M
↑ 17.57%
Net Income
-20.6M
↓ 41.26%
Net Profit Margin
-28.26%
↑ 28.31%
FY23Y/Y Change
Revenue
83.6M
↑ 14.84%
Net Income
-8.4M
↓ 58.99%
Net Profit Margin
-10.09%
↑ 18.17%
Q4 FY22Q/Q Change
Revenue
19.3M
↑ 3.33%
Net Income
-2.8M
↓ 41.05%
Net Profit Margin
-14.26%
↑ 10.74%
Q1 FY23Q/Q Change
Revenue
19.7M
↑ 1.84%
Net Income
-2.5M
↓ 10.68%
Net Profit Margin
-12.51%
↑ 1.75%
Q2 FY23Q/Q Change
Revenue
18.1M
↓ 8.07%
Net Income
-3.3M
↑ 34.35%
Net Profit Margin
-18.28%
↓ 5.77%
Q3 FY23Q/Q Change
Revenue
23.8M
↑ 31.48%
Net Income
-1.9M
↓ 43.36%
Net Profit Margin
-7.88%
↑ 10.4%
Q4 FY23Q/Q Change
Revenue
22.1M
↓ 7.06%
Net Income
-1.5M
↓ 19.23%
Net Profit Margin
-6.84%
↑ 1.04%
Q1 FY24Q/Q Change
Revenue
22.7M
↑ 2.64%
Net Income
-1.7M
↑ 14.48%
Net Profit Margin
-7.63%
↓ 0.79%
FY18Y/Y Change
Total Assets
52.6M
↓ 10.59%
Total Liabilities
25.3M
↓ 2.26%
FY19Y/Y Change
Total Assets
44.3M
↓ 15.68%
Total Liabilities
24.0M
↓ 5.08%
FY20Y/Y Change
Total Assets
77.7M
↑ 75.44%
Total Liabilities
43.6M
↑ 81.6%
FY21Y/Y Change
Total Assets
48.6M
↓ 37.52%
Total Liabilities
46.0M
↑ 5.65%
FY22Y/Y Change
Total Assets
46.6M
↓ 3.99%
Total Liabilities
32.5M
↓ 29.34%
FY23Y/Y Change
Total Assets
52.2M
↑ 11.88%
Total Liabilities
30.9M
↓ 5.06%
Q4 FY22Q/Q Change
Total Assets
46.6M
↓ 13.94%
Total Liabilities
32.5M
↓ 14.51%
Q1 FY23Q/Q Change
Total Assets
40.5M
↓ 13.22%
Total Liabilities
27.9M
↓ 14.14%
Q2 FY23Q/Q Change
Total Assets
38.0M
↓ 6.02%
Total Liabilities
28.5M
↑ 2.07%
Q3 FY23Q/Q Change
Total Assets
52.6M
↑ 38.3%
Total Liabilities
31.1M
↑ 9.05%
Q4 FY23Q/Q Change
Total Assets
52.2M
↓ 0.82%
Total Liabilities
30.9M
↓ 0.66%
Q1 FY24Q/Q Change
Total Assets
50.7M
↓ 2.78%
Total Liabilities
30.1M
↓ 2.6%
FY18Y/Y Change
Operating Cash Flow
-20.4M
↓ 3.29%
Investing Cash Flow
12.7M
↓ 12.27%
Financing Cash Flow
22.0M
↓ 1116.97%
FY19Y/Y Change
Operating Cash Flow
-27.3M
↑ 33.47%
Investing Cash Flow
-4.7M
↓ 137.33%
Financing Cash Flow
21.1M
↓ 4.17%
FY20Y/Y Change
Operating Cash Flow
-29.6M
↑ 8.76%
Investing Cash Flow
3.2M
↓ 167.62%
Financing Cash Flow
63.3M
↑ 200.29%
FY21Y/Y Change
Operating Cash Flow
-33.5M
↑ 13.13%
Investing Cash Flow
311.0K
↓ 90.32%
Financing Cash Flow
-2.2M
↓ 103.44%
FY22Y/Y Change
Operating Cash Flow
-17.4M
↓ 48.07%
Investing Cash Flow
-2.4M
↓ 870.42%
Financing Cash Flow
16.6M
↓ 863.29%
Q4 FY22Q/Q Change
Operating Cash Flow
-594.0K
↓ 46.1%
Investing Cash Flow
3.2M
↓ 121.9%
Financing Cash Flow
-5.5M
↑ 174.83%
Q1 FY23Q/Q Change
Operating Cash Flow
-3.9M
↑ 552.53%
Investing Cash Flow
5.3M
↑ 64.76%
Financing Cash Flow
-631.0K
↓ 88.53%
Q2 FY23Q/Q Change
Operating Cash Flow
-1.7M
↓ 55.11%
Investing Cash Flow
-64.0K
↓ 101.21%
Financing Cash Flow
-130.0K
↓ 79.4%

Technicals Summary

Sell

Neutral

Buy

Rockwell Medical Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Rockwell Medical Inc
Rockwell Medical Inc
15.76%
43.92%
-48.18%
-76.09%
-93.46%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
8.19%
11.16%
53.52%
51.66%
68.39%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
4.95%
4.83%
7.49%
20.11%
20.11%
Zoetis Inc.
Zoetis Inc.
4.51%
-7.23%
4.7%
-10.17%
57.65%
Viatris Inc.
Viatris Inc.
8.18%
-4.34%
9.23%
-19.25%
-31.21%
Catalent, Inc.
Catalent, Inc.
2.88%
16.51%
24.5%
-49.19%
6.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Rockwell Medical Inc
Rockwell Medical Inc
NA
NA
-0.79
-0.13
-0.51
-0.09
NA
0.7
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
40.06
40.06
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.33
29.33
1.69
0.38
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
33.43
33.43
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Rockwell Medical Inc
Rockwell Medical Inc
Buy
$58.5M
-93.46%
NA
-9.72%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.8B
68.39%
40.06
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.2B
20.11%
29.33
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$79.2B
57.65%
33.43
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.0B
-31.21%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.4B
6.67%
211.02
-28.44%

Institutional Holdings

  • Armistice Capital, LLC

    8.67%
  • Vanguard Group Inc

    3.69%
  • Perkins Capital Management Inc

    1.15%
  • Richmond Brothers Inc

    1.06%
  • Geode Capital Management, LLC

    0.95%
  • BlackRock Inc

    0.59%

Company Information

rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www

Organization
Rockwell Medical Inc
Employees
237
CEO
Dr. Mark Strobeck Ph.D.
Industry
Health Technology

FAQs